Biodegradable polymeric system for cisplatin delivery: Development, in vitro characterization and investigation of toxicity profile

Materials Science and Engineering C

Volumn 38, Issue 1, 2014, Pages 85-93

  Alam, Noor ^a   Khare, Vaibhav ^a   Dubey, Ravindra ^a   Saneja, Ankit ^a   Kushwaha, Manoj ^a   Singh, Gurdarshan ^a   Sharma, Neelam ^a   Chandan, Balkrishan ^a   Gupta, Prem N ^a  

^a CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

Author keywords

Biodistribution; Cisplatin; Nanoparticle; Nephrotoxicity; Poly (d,l lactic co glycolic) acid

Indexed keywords

BIOMATERIAL; CISPLATIN; CREATININE; LACTIC ACID; NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL; BAGG ALBINO MOUSE; BLOOD; BODY WEIGHT; CELL DEATH; CHEMISTRY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; FEMALE; HUMAN; INFRARED SPECTROSCOPY; MASS SPECTROMETRY; MOUSE; PARTICLE SIZE; STATIC ELECTRICITY; TISSUE DISTRIBUTION; TOXICITY TESTING; TUMOR CELL LINE; ULTRASTRUCTURE; UREA NITROGEN BLOOD LEVEL;

ANIMALS; BIOCOMPATIBLE MATERIALS; BLOOD UREA NITROGEN; BODY WEIGHT; CALORIMETRY, DIFFERENTIAL SCANNING; CELL DEATH; CELL LINE, TUMOR; CISPLATIN; CREATININE; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LACTIC ACID; MASS SPECTROMETRY; MICE; MICE, INBRED BALB C; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; STATIC ELECTRICITY; TISSUE DISTRIBUTION; TOXICITY TESTS;

EID: 84894051874     PISSN: 09284931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.msec.2014.01.043     Document Type: Article

References (54)

1. B. Rosenberg Platinum complexes for the treatment of cancer Interdisc. Sci. Rev. 3 1978 134 147
2. I. Kostova Platinum complexes as anticancer agents Recent Patents Anticancer Drug Discov. 1 2006 1 22
3. D. Wang, and S.J. Lippard Cellular processing of platinum anticancer drugs Nat. Rev. Drug Discov. 4 2005 307 320 (Pubitemid 41130944)
4. S.M. Cohen, and S.J. Lippard Cisplatin: from DNA damage to cancer chemotherapy Prog. Nucleic Acid Res. Mol. Biol. 67 2001 93 130 (Pubitemid 33804642)
5. I. Arany, and R.L. Safirstein Cisplatin nephrotoxicity Seminars in nephrology vol. 23 2003 Elsevier 460 464 (Pubitemid 37176691)
6. Z.H. Siddik Cisplatin: mode of cytotoxic action and molecular basis of resistance Oncogene 22 2003 7265 7279 (Pubitemid 37487159)
7. L.M. Pasetto, M.R. D'Andrea, A.A. Brandes, E. Rossi, and S. Monfardini The development of platinum compounds and their possible combination Crit. Rev. Oncol. Hematol. 60 2006 59 75 (Pubitemid 44404105)
8. T. Uehara, H. Watanabe, F. Itoh, S. Inoue, H. Koshida, M. Nakamura, J. Yamate, and T. Maruyama Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats Arch. Toxicol. 79 2005 451 460 (Pubitemid 41191383)
9. T.L. Cornelison, and E. Reed Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin Gynecol. Oncol. 50 1993 147 158 (Pubitemid 23275196)
10. D.F. Bajorin, G.J. Bosl, N.W. Alcock, D. Niedzwiecki, E. Gallina, and B. Shurgot Pharmacokinetics of cis-diamminedichloroplatinum (II) after administration in hypertonic saline Cancer Res. 46 1986 5969 5972 (Pubitemid 17178013)
11. T. Furukawa, K. Kumai, T. Kubota, S. Hirahata, H. Shimizu, H. Matsui, T. Takahara, K.-I. Aizawa, S. Shibata, and A. Shimada Experimental and clinical studies on the intraperitoneal administration of cis-diamminedichloroplatinum (II) for peritoneal carcinomatosis caused by gastric cancers Surg. Today 23 1993 298 306 (Pubitemid 23107566)
12. K.B. Meyer, and N.E. Madias Cisplatin nephrotoxicity Miner. Electrolyte Metab. 20 1993 201 213 (Pubitemid 24320004)
13. A.E.M. Vickers, K. Rose, R. Fisher, M. Saulnier, P. Sahota, and P. Bentley Kidney slices of human and rat to characterize cisplatin-induced injury on cellular pathways and morphology Toxicol. Pathol. 32 2004 577 590 (Pubitemid 39258463)
14. S.S. Bielack, R. Erttmann, G. Looft, C. Purfurst, G. Delling, K. Winkler, and G. Landbeck Platinum disposition after intraarterial and intravenous infusion of cisplatin for osteosarcoma Cancer Chemother. Pharmacol. 24 1989 376 380 (Pubitemid 19239316)
15. W.W. Eckman, C.S. Patlak, and J.D. Fenstermacher A critical evaluation of the principles governing the advantages of intra-arterial infusions J. Pharmacokinet. Biopharm. 2 1974 257 285
16. G. Lukas, S.D. Brindle, and P. Greengard The route of absorption of intraperitoneally administered compounds J. Pharmacol. Exp. Ther. 178 1971 562 566
17. N. Malik, E.G. Evagorou, and R. Duncan Dendrimer-platinate: a novel approach to cancer chemotherapy Anticancer Drugs 10 1999 767 776 (Pubitemid 30015678)
18. E. Gianasi, M. Wasil, E.G. Evagorou, A. Keddle, G. Wilson, and R. Duncan HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo Eur. J. Cancer 35 1999 994 1002 (Pubitemid 29277137)
19. M.S. Newman, G.T. Colbern, P.K. Working, C. Engbers, and M.A. Amantea Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice Cancer Chemother. Pharmacol. 43 1999 1 7 (Pubitemid 29048341)
20. N. Nishiyama, Y. Kato, Y. Sugiyama, and K. Kataoka Cisplatin-loaded polymer-metal complex micelle with time-modulated decaying property as a novel drug delivery system Pharm. Res. 18 2001 1035 1041 (Pubitemid 32799952)
21. M.J. Deurioo, W. Kop, O. van Tellingen, H. Bartelink, and A.C. Begg Intratumoural administration of cisplatin in slow-release devices: II. Pharmacokinetics and intratumoural distribution Cancer Chemother. Pharmacol. 27 1991 347 353
22. A. Hagiwara, T. Takahashi, K. Sawai, C. Sakakura, H. Tsujimoto, K. Osaki, T. Sakakibara, T. Ohyama, M. Ohgaki, and S. Muranishi Clinical trials with intraperitoneal cisplatin microspheres for malignant ascites - a pilot study Anticancer Drug Des. 8 1993 463
23. D. Moreno, S. Zalba, I. Navarro, C. Tros de Ilarduya, and M.J. Garrido Pharmacodynamics of cisplatin-loaded PLGA nanoparticles administered to tumor-bearing mice Eur. J. Pharm. Biopharm. 74 2010 265 274
24. K. Avgoustakis, A. Beletsi, Z. Panagi, P. Klepetsanis, A.G. Karydas, and D.S. Ithakissios PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties J. Control. Release 79 2002 123 135 (Pubitemid 34164166)
25. S. Kishimoto, Y. Kawazoe, M. Ikeno, S. Fukushima, and Y. Takeuchi Continuous exposure to low-dose cisplatin and apoptosis Biol. Pharm. Bull. 28 2005 1954 1957 (Pubitemid 41437088)
26. R. Verrijk, I.J.H. Smolders, N. Bosnie, and A.C. Begg Reduction of systemic exposure and toxicity of cisplatin by encapsulation in poly-lactide-co-glycolide Cancer Res. 52 1992 6653 6656
27. J.H. Kim, Y.-S. Kim, K. Park, S. Lee, H.Y. Nam, K.H. Min, H.G. Jo, J.H. Park, K. Choi, and S.Y. Jeong Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice J. Control. Release 127 2008 41 49
28. D. Moreno, S. Zalba, H. Colom, I.F. Troconiz, C. Tros de Ilarduya, and M.J. Garrido Biopharmaceutic and pharmacodynamic modeling of the in vitro antiproliferative effect of new controlled delivery systems of cisplatin Eur. J. Pharm. Sci. 37 2009 341 350
29. M. Meng, R. Kuntz, A. Fontanet, and P.K. Bennett A Novel Approach to qantify unbound cisplatin, carboplatin, and oxaliplatin in human plasma ultrafltrate by measuring platinum-DDTC complex using LC/MS/MS ASMS conference, Seattle, WA 2006 1 13
30. P. Houghton, R. Fang, I. Techatanawat, G. Steventon, P.J. Hylands, and C.C. Lee The sulphorhodamine (SRB) assay and other approaches to testing plant extracts and derived compounds for activities related to reputed anticancer activity Methods 42 2007 377 387 (Pubitemid 46860387)
31. D. Moreno, C.T. De Ilarduya, E. Bandres, M.A. Bunuales, M. Azcona, J. Garcia-Foncillas, and M.J. Garrido Characterization of cisplatin cytotoxicity delivered from PLGA-systems Eur. J. Pharm. Biopharm. 68 2008 503 512 (Pubitemid 351318205)
32. P.V. Pierre, I. Wallin, S. Eksborg, and H. Ehrsson Quantitative liquid chromatographic determination of intact cisplatin in blood with microwave-assisted post-column derivatization and UV detection J. Pharm. Biomed. Anal. 56 2011 126 130
33. X. Yan, and R.A. Gemeinhart Cisplatin delivery from poly (acrylic acid-co-methyl methacrylate) microparticles J. Control. Release 106 2005 198 208 (Pubitemid 41149078)
34. S.W. Jung, Y.I. Jeong, Y.H. Kim, K.C. Choi, and S.-H. Kim Drug release from core-shell type nanoparticles of poly (DL-lactide-co-glycolide)-grafted dextran J. Microencapsul. 22 2005 901 911 (Pubitemid 43158191)
35. K. Nakamoto Infrared and Raman Spectra of Inorganic and Coordination Compounds: Part B., Applications in Coordination, Organometallic, and Bioinorganic Chemistry sixth ed. 2009 Wiley Hoboken, New Jersey
36. S. Torrado, and S. Torrado Characterization of physical state of mannitol after freeze-drying: effect of acetylsalicylic acid as a second crystalline cosolute Chem. Pharm. Bull. 50 2002 567 570 (Pubitemid 41694920)
37. W.K. Kim, and Y.E. Kwon Comparative nephrotoxicity of cisplatin and new octahedral Pt (IV) complexes Cancer Chemother. Pharmacol. 60 2007 237 243
38. D. Huo, S. Deng, L. Li, and J. Ji Studies on the poly (lactic-co-glycolic) acid microspheres of cisplatin for lung-targeting Int. J. Pharm. 289 2005 63 67 (Pubitemid 40093541)
39. J. Fujiyama, Y. Nakase, K. Osaki, C. Sakakura, H. Yamagishi, and A. Hagiwara Cisplatin incorporated in microspheres: development and fundamental studies for its clinical application J. Control. Release 89 2003 397 408 (Pubitemid 36555899)
40. Y. Li, S. Lim, and C.P. Ooi Fabrication of cisplatin-loaded poly (lactide-co-glycolide) composite microspheres for osteosarcoma treatment Pharm. Res. 29 2012 756 769
41. A.M. Reed, and D.K. Gilding Biodegradable polymers for use in surgery-poly (glycolic)/poly (lactic acid) homo and copolymers: 2. In vitro degradation Polymer 22 1981 494 498 (Pubitemid 11499831)
42. R. Gref, Y. Minamitake, M.T. Peracchia, V. Trubetskoy, V. Torchilin, and R. Langer Biodegradable long-circulating polymeric nanospheres Science 263 1994 1600 1603 (Pubitemid 24128361)
43. T. Tamura, F. Fujita, M. Tanimoto, M. Koike, A. Suzuki, M. Fujita, Y. Horikiri, Y. Sakamoto, T. Suzuki, and H. Yoshino Anti-tumor effect of intraperitoneal administration of cisplatin-loaded microspheres to human tumor xenografted nude mice J. Control. Release 80 2002 295 307 (Pubitemid 34273767)
44. L. Garcia-Contreras, K. Abu-Izza, and D.R. Lu Biodegradable cisplatin microspheres for direct brain injection: preparation and characterization Pharm. Dev. Technol. 2 1997 53 65 (Pubitemid 28257332)
45. U.A.Th. Brinkman, G. DeVries, and R. Kuroda Thin-layer chromatographic data for inorganic substances J. Chromatogr. 85 1973 187 526
46. O.H. Drummer, A. Proudfoot, L. Howes, and J.L. William High-performance liquid chromatographic determination of platinum (II) in plasma ultrafiltrate and urine: comparison with a flameless atomic absorption spectrometric method Clin. Chim. Acta 136 1984 65 74 (Pubitemid 14213322)
47. J. Panyam, D. Williams, A. Dash, D. Leslie-Pelecky, and V. Labhasetwar Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles J. Pharm. Sci. 93 2004 1804 1814 (Pubitemid 38823706)
48. F. Nemati, C. Dubernet, A.C. De Ve'rdiare, M.F. Poupon, L. Treupel-Acar, F. Puisieux, and P. Couvreur Some parameters influencing cytotoxicity of free doxorubicin and doxorubicin-loaded nanoparticles in sensitive and multidrug resistant leucemic murine cells: incubation time, number of nanoparticles per cell Int. J. Pharm. 102 1994 55 62
49. S.K. Sahoo, A.K. Panda, and V. Labhasetwar Characterization of porous PLGA/PLA microparticles as a scaffold for three dimensional growth of breast cancer cells Biomacromolecules 6 2005 1132 1139 (Pubitemid 40467862)
50. J.C. Leroux, E. Doelker, and R. Gurny The use of drug-loaded nanoparticles in cancer chemotherapy S. Benita, Microencapsulation: Methods and Industrial Applications 1996 Marcel Dekker New York 535 575
51. N. Pabla, and Z. Dong Cisplatin nephrotoxicity: mechanisms and renoprotective strategies Kidney Int. 73 2008 994 1007 (Pubitemid 351543900)
52. X. Yao, K. Panichpisal, N. Kurtzman, and K. Nugent Cisplatin nephrotoxicity: a review Am. J. Med. Sci. 334 2007 115 124 (Pubitemid 47262919)
53. H.S. Choi, W. Liu, P. Misra, E. Tanaka, J.P. Zimmer, B. Itty Ipe, M.G. Bawendi, and J.V. Frangioni Renal clearance of quantum dots Nat. Biotechnol. 25 2007 1165 1170 (Pubitemid 47538116)
54. L.D. Lagasse, R.G. Pretorius, E.S. Petrilli, L.C. Ford, J. Hoeschele, and C. Kean The metabolism of cis-dichlorodiammineplatinum (II): distribution, clearance, and toxicity Am. J. Obstet. Gynecol. 139 1981 791 798 (Pubitemid 11126041)